Figure 1
Proportion of refractory multiple myeloma patients surviving after treatment with high-dose cyclophosphamide over time (wks). Median overall survival was not reached, and the estimated one year survival was 52.5% (SE 20.4%).
Proportion of refractory multiple myeloma patients surviving after treatment with high-dose cyclophosphamide over time (wks). Median overall survival was not reached, and the estimated one year survival was 52.5% (SE 20.4%).
